Lobe Sciences Ltd. is a life sciences company focused on researching and advancing psychedelic-based medicines. Their primary therapeutic development involves psilocybin-derived treatments combined with N-acetylcysteine, specifically for addressing mild traumatic brain injuries (mTBI) and post-traumatic stress disorder (PTSD). Additionally, they engineer specialized devices aimed at enhancing the efficiency of drug administration. This organization, headquartered in Vancouver, Canada, underwent a name change from Greenstar Biosciences Corp. to Lobe Sciences Ltd. in November 2020.